zliming2004

Venetoclax, a small-molecule bcl-2 inhibitor

Venetoclax, a small-molecule bcl-2 inhibitor, is in phase III clinical trials at Abbvie in collaboration with Genentech for the oral treatment of patients with chronic lymphocytic leukemia (CLL). Phase II trials are also underway at Abbvie and Genentech for acute myeloid leukemia (AML), diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma. Early clinical development has been initiated at Abbvie for multiple myeloma, non-Hodgkin's lymphoma, mantle cell lymphoma and systemic lupus erythematosus.

By April 2011, Abbott (now AbbVie) and Genentech, had agreed to collaborate on the development of venetoclax. In September and December 2013, venetoclax was granted Orphan Drug designation for CLL in the US and EU, respectively. In March 2014, further orphan drug designation was granted in the US for DLBCL. In 2015, the compound was granted breakthrough therapy designation by the FDA for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia with a 17p deletion.

 Phase Organization ConditionPhase IIIAbbVie
GenentechLeukemia, chronic lymphocyticPhase IIAbbVieLeukemia, acute myeloidPhase IIGenentechLymphoma, diffuse large B-cellPhase IIGenentechLymphoma, follicularPhase IAbbVieLymphoma, mantle cellPhase IGenentechLymphoma, non-Hodgkin'sPhase IAbbVie
GenentechMultiple myelomaPhase IAbbVieSystemic lupus erythematosus

2015年06月18日 - zliming2004 - zliming2004的博客

 

2015年06月18日 - zliming2004 - zliming2004的博客

 

2015年06月18日 - zliming2004 - zliming2004的博客

  Patent NumberApplicantTitleConditionSubject MatterUS 2014094471
EP 2435432
CN 102448959
US 2012190688
US 2014113910
US 8546399
US 8580794
US 2013267534
US 2013267514
WO 2010138588
US 2010305122
KR 2012034671
US 9045475
US 9034875
  AbbVie Bahamas Ltd.   Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases2015年06月18日 - zliming2004 - zliming2004的博客  

Cancer

2015年06月18日 - zliming2004 - zliming2004的博客  Drug Substances
 EP 2576546
CN 103153993
JP 2013527202
KR 2013116002
US 2011124628
WO 2011149492
  AbbVie Inc.   Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases2015年06月18日 - zliming2004 - zliming2004的博客  

Cancer

2015年06月18日 - zliming2004 - zliming2004的博客  Drug Substances
 US 2012277210
KR 2014056137
JP 2013540823
EP 2632436
CN 103167867
WO 2012058392
US 2015157639
  AbbVie Inc.   Solid dispersions containing an apoptosis-inducing agent2015年06月18日 - zliming2004 - zliming2004的博客  

Immunological Disorders

Leukemia, acute lymphocytic

Leukemia, chronic lymphocytic

Lymphoma, non-Hodgkin's

2015年06月18日 - zliming2004 - zliming2004的博客  Dosage Forms and Compositions
 WO 2012121758
KR 2014052921
EP 2613769
CN 103282025
US 2012108590
  AbbVie Inc.   Melt-extruded solid dispersions containing an apoptosis-inducing agent2015年06月18日 - zliming2004 - zliming2004的博客  

Autoimmune disease

Lymphoma, non-Hodgkin's

2015年06月18日 - zliming2004 - zliming2004的博客  Dosage Forms and Compositions
 US 2014275540
US 9006438
  AbbVie Inc.   Processes for the preparation of an apoptosis-inducing agent2015年06月18日 - zliming2004 - zliming2004的博客  

Leukemia, chronic lymphocytic

2015年06月18日 - zliming2004 - zliming2004的博客  Synthesis
 WO 2014165044
  AbbVie Inc.   Processes for the preparation of an apoptosis-inducing agent2015年06月18日 - zliming2004 - zliming2004的博客  

Leukemia, chronic lymphocytic

2015年06月18日 - zliming2004 - zliming2004的博客  Synthesis
 

评论